	US 12,291,710 B2
	Antisense oligonucleotide targeting ATN1 mRNA or pre-mRNA
Takao Kawano, Kyoto (JP); Toshiaki Ode, Kyoto (JP); Akie Chiba, Ibaraki (JP); Osamu Onodera, Niigata (JP); Taisuke Kato, Niigata (JP); and Sachiko Hirokawa, Niigata (JP)
Assigned to Nippon Shinyaku Co., Ltd., Kyoto (JP); and Niigata University, Niigata (JP)
Filed by NIPPON SHINYAKU CO., LTD., Kyoto (JP); and NIIGATA UNIVERSITY, Niigata (JP)
Filed on Jun. 12, 2024, as Appl. No. 18/741,110.
Application 18/741,110 is a continuation of application No. PCT/JP2022/045921, filed on Dec. 13, 2022.
Claims priority of application No. 2021-201756 (JP), filed on Dec. 13, 2021; and application No. 2022-184853 (JP), filed on Nov. 18, 2022.
Prior Publication US 2024/0318181 A1, Sep. 26, 2024
Int. Cl. C12N 15/113 (2010.01); A61P 25/28 (2006.01)

CPC C12N 15/113 (2013.01) [A61P 25/28 (2018.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/341 (2013.01); C12N 2310/3525 (2013.01)]

18 Claims

1. An antisense oligonucleotide, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, comprising the nucleic acid sequence of SEQ ID NO: 133, wherein the antisense oligonucleotide is 20 nucleotides long.